Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients

Pharmacogenetics and Genomics

Volumn 21, Issue 7, 2011, Pages 417-425

  Muntinghe, Friso L H ^a   Vegter, Stefan ^a,b   Verduijn, Marion ^c   Boeschoten, Elisabeth W ^d   Dekker, Friedo W ^c   Navis, Gerjan ^a   Postma, Maarten ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Hans Mak Institute   (Netherlands)

Author keywords

CC chemokine receptor 5; chemokine receptor cost effectiveness; dialysis; Mendelian; polymorphism

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; WILD TYPE;

EID: 79959792151     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283472990     Document Type: Article

References (63)

1. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-1407.
2. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373:1009-1015.
3. DiMasi JA, Grabowski HG, Vernon J. R&D costs and returns by therapeutic category. Clinical and Non-Clinical Drug Development 2004; 38:211-223. (Pubitemid 39121144)
4. Hingorani A, Humphries S. Nature's randomised trials. Lancet 2005; 366:1906-1908. (Pubitemid 41713974)
5. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004; 33:30-42. (Pubitemid 38528650)
6. Verduijn M, Siegerink B, Jager KJ, Zoccali C, Dekker FW. Mendelian randomization: use of genetics to enable causal inference in observational studies. Nephrol Dial Transplant 2010; 25:1394-1398.
7. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology 2006; 11:36-41.
8. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565-568. (Pubitemid 28207705)
9. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008; 28:1897-1908.
10. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8:802-815.
11. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106:1523-1529.
12. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94:253-261. (Pubitemid 38197459)
13. Van Wanrooij EJ, Happe H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, et al. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25:2642-2647. (Pubitemid 43732291)
14. Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 1997; 272:30603-30606. (Pubitemid 27527488)
15. Gonzalez P, Alvarez R, Batalla A, Reguero JR, Alvarez V, Astudillo A, et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2001; 2:191-195. (Pubitemid 33676982)
16. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001; 158:233-239. (Pubitemid 32735489)
17. Pai JK, Kraft P, Cannuscio CC, Manson JE, Rexrode KM, Albert CM, et al. Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 2006; 186:132-139.
18. Muntinghe FL, Gross S, Bakker SJ, Landman GW, van der Harst P, Bilo HJ, et al. CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus. Diabetes Res Clin Pract 2009; 86:140-145.
19. Muntinghe FL, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 2009; 20:1641-1649.
20. Kovesdy CP, Kalantar-Zadeh K. Do genes allow inflammation to kill or not to kill? J Am Soc Nephrol 2009; 20:1429-1431.
21. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11:1170-1172. (Pubitemid 43093663)
22. Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26:569-587. (Pubitemid 351871553)
23. Vegter S, Jansen E, Postma MJ, Boersma C. Economic Evaluations of pharmacogenetic and genomic screening programs: update of the literature. Drug Development Research 2010; 71:492-501.
24. Stenvinkel P, Wanner C, Metzger T, Heimburger O, Mallamaci F, Tripepi G, et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62:1791-1798. (Pubitemid 35286288)
25. Grootendorst DC, de Jager DJ, Brandenburg VM, Boeschoten EW, Krediet RT, Dekker FW. Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients-no additional power for mortality prediction with high-sensitivity CRP. Nephrol Dial Transplant 2007; 22:3277-3284. (Pubitemid 350202555)
26. den Elzen WP, van Manen JG, Boeschoten EW, Krediet RT, Dekker FW. The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant 2006; 21:1588-1595. (Pubitemid 43834640)
27. Clark VJ, Metheny N, Dean M, Peterson RJ. Statistical estimation and pedigree analysis of CCR2-CCR5 haplotypes. Hum Genet 2001; 108:484-493. (Pubitemid 32700350)
28. Van Dijk PC, Jager KJ, de Charro F, Collart F, Cornet R, Dekker FW, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001; 16:1120-1129. (Pubitemid 32547364)
29. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
30. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13:397-409. (Pubitemid 28140699)
31. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998; 44:215-232. (Pubitemid 28345184)
32. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35:1095-1108. (Pubitemid 127453463)
33. Sennfalt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis - a cost-utility analysis. Perit Dial Int 2002; 22:39-47. (Pubitemid 34326578)
34. Rozenbaum MH, Hoek AJ, Hak E, Postma MJ. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine 2010; 28:2367-2369.
35. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
36. Vegter S, Perna A, Hiddema W, Ruggenenti P, Remuzzi G, Navis G, et al. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenet Genomics 2009; 19:695-703.
37. Dutch Health Care Insurance Board. Dutch drug prices [in Dutch]. 2010. Available at http://www.medicijnkosten.nl.
38. Wong A, Kommer GJ, Polder JJ. Life-course and healthcare costsbackground report [in Dutch]. The National Institute for Public Health and the Environment (RIVM), 2008. Available at http://www.rivm.nl/bibliotheek/ rapporten/270082001. pdf .
39. Van Hout BA, Simeon GP, McDonnell J, Mann JF. Economic evaluation of benazepril in chronic renal insufficiency. Kidney Int Suppl 1997; 63:S159-S162. (Pubitemid 28020458)
40. Lee RH. Future costs in cost effectiveness analysis. J Health Econ 2008; 27:809-818.
41. Rappange DR, van Baal PH, van Exel NJ, Feenstra TL, Rutten FF, BrouwerWB. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics 2008; 26:815-830.
42. ISPOR. Pharmacoeconomic Guidelines Around The World. 2010. Available at http://www,ispor.org/peguideines/index.asp.
43. Oostenbrink JB, Bouwmans CA, Koopmanschap MA, Rutten FF. Guideline for costing research, methods and standardized prices for economic evaluations in health care. Diemen, The Netherlands: Health Care Insurance Board; 2004.
44. Gold M, Siegel J, Russell L. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
45. Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. Health care costs, quality, and outcomes-ispor book of terms. Lawrenceville, NJ: International Society of Pharmacoeconomics and Outcomes Research (ISPOR); 2003.
46. Ebrahim S, Davey SG. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet 2008; 123:15-33.
47. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005; 331:446-448. (Pubitemid 41176388)
48. Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010; 121:52-62.
49. Franco OH, Steyerberg EW, de Laet C. The polypill: at what price would it become cost effective? J Epidemiol Community Health 2006; 60:213-217. (Pubitemid 43288626)
50. Haddow J, Palomaki G. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W, editors. Human genome epidemiology. Oxford: Oxford University Press; 2004.
51. Sanderson S, Zimmern R, Kroese M, Higgins J, Patch C, Emery J. How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genet Med 2005; 7:495-500. (Pubitemid 41445490)
52. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16:1-31. (Pubitemid 27224092)
53. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16:33-64. (Pubitemid 27224093)
54. Winkelmayer WC,Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002; 22:417-430.
55. Manns B, Meltzer D, Taub K, Donaldson C. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. J Health Econ 2003; 12:949-958. (Pubitemid 37407339)
56. Brennan A, Akehurst R, Davis S, Sakai H, Abbott V. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health 2007; 10:32-41. (Pubitemid 46161093)
57. Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005; 8:549-561. (Pubitemid 41741815)
58. Ray JA, Borker R, Barber B, Valentine WJ, Belozeroff V, Palmer AJ. Costeffectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. Value Health 2008; 11:800-808.
59. Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007; 11:iii. xi-iii,167.
60. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007; 22:2867-2878. (Pubitemid 350093448)
61. Quinn RR, Naimark DM, Oliver MJ, Bayoumi AM. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A costutility analysis. Am J Kidney Dis 2007; 50:421-432. (Pubitemid 47304400)
62. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ. The costeffectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003; 64:295-304. (Pubitemid 36714184)
63. Kasserra C, Sansone-Parsons A, Keung A, Tetteh E, Assaf M, O'Mara E, et al. Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen. Clin Pharmacokinet 2010; 49:397-406.